renal transplantion
Conditions
Interventions
Kidney transplant patients with proteinuria receiving Dapagliflozin and no Dapagliflozin treatment group:none
Sponsors
Department of Nephrology, West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18; 2. First renal transplant, time from transplantation >= 3 months; 3. Standard immunosuppression consisted of a triple drug regimen including CNI, prednisolone and mycophenolate mofetil, receiving the maximum licensed dose of ACEi/ARB >= 4 weeks; 4. Patients who are routine visitors to the outpatient clinics for follow-ups at West China Hospital of Sichuan University; 5. Urinary albumin-to-creatinine ratio (UACR) between 30 mg/g and 5000 mg/g; 6. Stable renal function, with an eGFR >= 25 mL/min/1.73^2 and a decrease in eGFR <25% from baseline over the past 3 months.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes mellitus; 2. Preparation for pregnancy, pregnancy, or lactation,; 3. With malignant tumors or serious organ dysfunction; 4. History of recurrent or persistent hypotension, or shock; 5. Severe hypoglycemia within the past 3 months or have had episodes of unconsciousness due to hypoglycemia; 6. Recurrent urinary tract infections or genital infections within the past 6 months; 7. Severe peripheral vascular disease (i.e, history of amputation, gangrene, non-healing ulcers, ischemic rest pain); 8. NYHA class IV congestive heart failure at inclusion; 9. Urinary albumin-to-creatinine ratio (UACR) >5000 mg/g; 10. Renal artery stenosis in transplanted kidney; 11. Stroke, transient ischemic attack, myocardial infarction, or unstable angina within the 12 weeks; 12. With concomitant autoimmune diseases such as systemic lupus erythematosus or ANCA-associated vasculitis; 13. Abnormal liver function (AST or ALT > 3 times upper limit of normal; or total bilirubin > 2 times upper limit of normal); 14. Participation in other clinical trials; 15. Comorbidities with a prognosis of less than 2 years life expectancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary albumin-to-creatinine ratio (UACR);urinary protein-to-creatinine ratio (PCR);24-hour urinary protein quantification; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum creatinine;eGFR;qualitative urine protein test;Tacrolimus trough concentration;serum electrolytes;fasting blood glucose;lipid profile;urine glucose; | — |
Countries
China
Contacts
Public ContactYunying Shi
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Outcome results
None listed